Uniform, luminescent Eu:LuF3 nanoparticles

A simple procedure for the synthesis of orthorhombic, uniform, LuF3 particles with two different morphologies (rhombus- and cocoon-like) and nanometer and sub-micrometer size, respectively, is reported. The method consists in the aging, at 120 °C for 2 h, a solution containing [BMIM]BF4 ionic liquid (0.5 mL) and lutetium acetate (in the case of the rhombi) or lutetium nitrate (in the case of the cocoons) (0.02 M) in ethylene glycol (total volume 10 mL). This synthesis method was also adequate for the synthesis of Eu3+-doped LuF3 particles of both morphologies, whose luminescence properties were investigated in detail. The experimental observations reported herein suggest that these materials are suitable phosphors for optoelectronic as well as in vitro biotechnological applications.MEC MAT2012-34919Junta de Andalucía JA FQM 06090CSIC 201460E00

Rare earth based nanostructured materials: Synthesis, functionalization, properties and bioimaging and biosensing applications

Rare earth based nanostructures constitute a type of functional materials widely used and studied in the recent literature. The purpose of this review is to provide a general and comprehensive overview of the current state of the art, with special focus on the commonly employed synthesis methods and functionalization strategies of rare earth based nanoparticles and on their different bioimaging and biosensing applications. The luminescent (including downconversion, upconversion and permanent luminescence) and magnetic properties of rare earth based nanoparticles, as well as their ability to absorb X-rays, will also be explained and connected with their luminescent, magnetic resonance and X-ray computed tomography bioimaging applications, respectively. This review is not only restricted to nanoparticles, and recent advances reported for in other nanostructures containing rare earths, such as metal organic frameworks and lanthanide complexes conjugated with biological structures, will also be commented on.European Union 267226Ministerio de Economía y Competitividad MAT2014-54852-

Crystal structure, NIR luminescence and X-ray computed tomography of Nd3+:Ba0.3Lu0.7F2.7 nanospheres

Uniform, hydrophilic 50 nm diameter Nd3+-doped Ba0.3Lu0.7F2.7 nanospheres are synthesized at 120 °C using a singular one-pot method based on the use of ethylene glycol as solvent, in the absence of any additive. The composition and crystal structure of the undoped material are analyzed in detail using ICP and XRD, which reveals a BaF2 cubic crystal structure that is able to incorporate 70 mol% of Lu ions. This finding contrasts with the reported phase diagram of the system, where the maximum solubility is around 30 mol% Lu. XRD proves as well that the Ba0.3Lu0.7F2.7 structure is able to incorporate Nd3+ ions up to, at least 10 mol%, without altering the uniform particles morphology. The Nd-doped particles exhibit nearinfrared luminescence when excited at 810 nm. The maximum emission intensity with the minimum concentration quenching effect is obtained at 1.5% Nd doping level. X-ray computed tomography experiments are carried out on powder samples of the latter composition. The sample significantly absorbs X-ray photons, thus demonstrating that the Nd3+-doped Ba0.3Lu0.7F2.7 nanospheres are good candidates as contrast agents in computed tomography.Ministerio de Economía y Competitividad MAT2014-54852-R, MAT2012-34919Consejo Superior de Investigaciones Científicas 201560E056, 201460E00

Ligand-Free Synthesis of Tunable Size Ln:BaGdF5 (Ln = Eu3+ and Nd3+) Nanoparticles: Luminescence, Magnetic Properties, and Biocompatibility

Bifunctional and highly uniform Ln:BaGdF5 (Ln = Eu3+ and Nd3+) nanoparticles have been successfully synthesized using a solvothermal method consisting of the aging at 120 °C of a glycerol solution containing the corresponding Lanthanide acetylacetonates and butylmethylimidazolium tetrafluoroborate. The absence of any surfactant in the synthesis process rendered hydrophilic nanospheres (with tunable diameter from 45 nm 85 nm, depending on the cations concentration of the starting solution) which are suitable for bioapplications. The particles are bifunctional because they showed both optical and magnetic properties due to the presence of the optically active lanthanides (Eu3+ in the visible and Nd3+ in the NIR regions of the electromagnetic spectrum) and the paramagnetic gadolinium ion, respectively. The luminescence decay curves of the nanospheres doped with different amounts of Eu3+ and Nd3+ have been recorded in order to determine the optimum dopant concentration in each case, which turned out to be 5% Eu3+ and 0.5% Nd3+. Likewise, proton relaxation times were measured at 1.5 T in water suspensions of the optimum particles found in the luminescence study. The values obtained suggested that both kinds of particles could be used as positive contrast agents for MRI. Finally, it was demonstrated that both the 5% Eu3+ and 0.5% Nd3+-doped BaGdF5 nanospheres showed negligible cytotoxicity for VERO cells for concentrations up to 0.25 mg mL–1.Peer reviewe

Manual de técnica forense I

Introducción -- Organización del Poder Judicial -- Órganos jurisdiccionales -- Anexos -- Servicios de administración -- Servicios de apoyo técnico -- Programa de fortalecimiento del Sistema Judicial Uruguayo – Anexo -- Organización de la Justicia Administrativa -- Estructura Orgánica del Ministerio Público y Fiscal – Anexo -- Competencia de los Tribunales -- Formalidades del Escrito Judicial -- Aspectos de forma que debe cumplir el Escrito Judicial -- Conclusión -- Conciliación previa -- La autocomposición del conflicto -- Elementos constitutivos y redacción de demanda -- De la suma – Invocación – Comparecencia -- Exordio y emplazamiento -- Capítulo de hechos -- Ofrecimiento de medios probatorios -- Capítulo de Derecho – Petitorio – Otrosíes – Firmas -- Tributación judicial y aplicación del arancel – Introducción – Tributación – Arancel -- Trámite judicial posterior -- Forma de presentación de la demanda -- Trámite posterior a la presentación de la demanda -- Notificación de la demanda -- Formas y plazos para contestar, oponer excepciones o reconvenir -- Actitudes del demandado -- Introducción Contestación -- Excepciones previas – Reconvención -- Contestación–citación en garantía -- Allanamiento a la pretensión -- Respuesta de expectativa -- Incomparecencia del demandado ante el traslado de la demanda -- Declaración de rebeldía -- Demanda y contestación conjunta -- Audiencia preliminar y complementaria -- Audiencia preliminar -- Audiencia complementaria – Alegatos – Introducción --¿Qué es un alegato para el Código General del Proceso y la práctica por él regulada? -- ¿Cómo construir un alegato? -- Forma de los alegatos – Sentencia – Concepto -- Clasificaciones -- Requisitos de la sentencia -- Eficacia de la sentencia --Recursos. Su interposición -- Los medios de impugnación -- Recursos de aclaración y ampliación -- Recursos de reposición y apelación -- Recurso de casación -- Recurso de revisión -- Recurso de queja --Medios extraordinarios de conclusión del proceso – Conciliación-transacción – Desistimiento -- Perención de la instancia -- Diligencias preparatorias -- Proceso cautelar (medidas cautelares) Formulación del escrito de solicitud de medida cautelar como diligencia prelimina

Europium doped-double sodium bismuth molybdate nanoparticles as contrast agents for luminescence bioimaging and X-ray computed tomography

A one-pot method for the synthesis of uniform Eu3+-doped NaBi(MoO4)2 nanoparticles with an ellipsoidal shape and tetragonal crystal structure functionalized with polyacrylic acid is reported for the first time in the literature. The method is based on a homogeneous precipitation reaction from solutions in an ethylene glycol/water medium containing appropriate bismuth, sodium, and molybdate precursors and polyacrylic acid. The luminescence properties (excitation and emission spectra and luminescence lifetime) of such nanoparticles are evaluated for different Eu3+ doping levels, finding an intense red emission for all synthesized samples. The X-ray attenuation properties of the nanoparticles have been also analyzed, which were found to be better than those of a commercially computed tomography contrast agent (iohexol). The dispersibility of the nanoparticles in a physiological medium was also analyzed, finding that they could be well dispersed in a 2-N-morpholinoethanesulfonic acid monohydrate medium (pH = 6.5). Finally, the cell viability of such a phosphor has been analyzed using MIA-PaCa-2 cells and its in vivo toxicity has been evaluated using the nematode Caenorhabditis elegans model finding no significant toxicity in both cases up to a nanoparticle concentration of 100 μg mL−1, which is within the range required for most in vivo applications. The developed Eu3+-doped NaBi(MoO4)2 nanoparticles are, therefore, excellent candidates for their use as bimodal probes for luminescence imaging and X-ray computed tomography

La filosofía entre el bachillerato y la universidad: Perspectivas docentes para la educación en el siglo XXI (II)

Se trata de la memoria final de las actividades del proyecto nº 106 de la convocatoria de Proyectos Innova-Docencia UCM 2020-2021

Year in review in Intensive Care Medicine 2010: III. ARDS and ALI, mechanical ventilation, noninvasive ventilation, weaning, endotracheal intubation, lung ultrasound and paediatrics

SCOPUS: re.jinfo:eu-repo/semantics/publishe

Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality

Hyperoxemia and excess oxygen use in early acute respiratory distress syndrome : Insights from the LUNG SAFE study

Publisher Copyright: © 2020 The Author(s). Copyright: Copyright 2020 Elsevier B.V., All rights reserved.Background: Concerns exist regarding the prevalence and impact of unnecessary oxygen use in patients with acute respiratory distress syndrome (ARDS). We examined this issue in patients with ARDS enrolled in the Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG SAFE) study. Methods: In this secondary analysis of the LUNG SAFE study, we wished to determine the prevalence and the outcomes associated with hyperoxemia on day 1, sustained hyperoxemia, and excessive oxygen use in patients with early ARDS. Patients who fulfilled criteria of ARDS on day 1 and day 2 of acute hypoxemic respiratory failure were categorized based on the presence of hyperoxemia (PaO2 > 100 mmHg) on day 1, sustained (i.e., present on day 1 and day 2) hyperoxemia, or excessive oxygen use (FIO2 ≥ 0.60 during hyperoxemia). Results: Of 2005 patients that met the inclusion criteria, 131 (6.5%) were hypoxemic (PaO2 < 55 mmHg), 607 (30%) had hyperoxemia on day 1, and 250 (12%) had sustained hyperoxemia. Excess FIO2 use occurred in 400 (66%) out of 607 patients with hyperoxemia. Excess FIO2 use decreased from day 1 to day 2 of ARDS, with most hyperoxemic patients on day 2 receiving relatively low FIO2. Multivariate analyses found no independent relationship between day 1 hyperoxemia, sustained hyperoxemia, or excess FIO2 use and adverse clinical outcomes. Mortality was 42% in patients with excess FIO2 use, compared to 39% in a propensity-matched sample of normoxemic (PaO2 55-100 mmHg) patients (P = 0.47). Conclusions: Hyperoxemia and excess oxygen use are both prevalent in early ARDS but are most often non-sustained. No relationship was found between hyperoxemia or excessive oxygen use and patient outcome in this cohort. Trial registration: LUNG-SAFE is registered with ClinicalTrials.gov, NCT02010073publishersversionPeer reviewe